|Bid||146.00 x 800|
|Ask||148.82 x 800|
|Day's range||148.06 - 151.99|
|52-week range||147.77 - 249.27|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||33.63|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||1.30 (0.87%)|
|Ex-dividend date||20 July 2022|
|1y target est||228.73|
PARSIPPANY, N.J. & RUTHERFORD, New South Wales, Australia, September 30, 2022--Zoetis Inc. (NYSE: ZTS) today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals. Jurox’s operations are based in Australia, with additional regional offices in New Zealand, U.S., Canada and the UK. Financial terms of the transaction, which was announced in
PARSIPPANY, N.J., September 29, 2022--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 3, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2022 financial results and respond to questions from financial analysts during the call.
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...